AbbVie Gastroenterology

AbbVie has been working to advance standards of care in gastroenterology for more than 10 years. Our expertise and dedication coupled with our drive for innovation creates a brighter future for patients.

A legacy of innovation

We have taken bold steps to shape the landscape in inflammatory bowel disease (IBD) management, striving to help patients achieve a better tomorrow. But we have more work to do. We are relentless in our quest to better understand patient needs and will continue to work closely with patients and partners to advance the quality of care in IBD.

Learn more about our gastroenterology focus areas:

A chronic inflammatory bowel disease characterized by inflammation of any part of the gastrointestinal tract. Symptoms vary from person to person and often fluctuate between active flare-ups and remission.

Characterized by inflammation of the large intestine, ulcerative colitis is a chronic inflammatory bowel disease. Symptoms range from mild to severe but may make it difficult to keep to a usual routine.

Pioneers in science

Leaving no patient behind

As we learn more about pathophysiology and optimal disease management we can set more ambitious goals for tackling IBD in ways that extend beyond symptoms. For example, tools like our IBD Disk and the Lémann score help us monitor more IBD patients to identify those with a poor prognosis. Unlocking effective treatment strategies is vital to helping modify the course of the disease.

Addressing unmet needs

We currently have over 30 ongoing or planned trials in IBD. By learning, adapting and innovating, AbbVie aspires to make IBD patients’ long-term goals possible.

Partnerships with purpose

We work with partners to tackle global challenges in IBD and shape the future of disease management. Together, we aim to enhance quality of care by educating on Treat to Target (T2T), demonstrating its clinical and economic impact, and making non-invasive monitoring standard for most patients.

Key pathways

TNF-α
A cytokine that contributes to the induction and maintenance of the inflammatory immune response.

IL-23
A cytokine that shares a subunit with IL-12 and works to mediate inflammatory responses.

JAK1

An enzyme that signals and initiates the response of other cytokines involved in the body’s immune response.

CD40
A protein receptor expressed by B cells, macrophages and dendritic cells that is involved in mediating inflammatory responses.

Committed to gastroenterology

Then and now: I won’t be defined by my Crohn’s disease

A letter from the future offers perspective and advice on living with Crohn’s disease.

Read more

In the news

Get the latest news about AbbVie
in immunology.

Visit our News Center